Business Context and Reporting Period
Company: Jupiter Neurosciences, Inc. (JUNS)
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2025
Event: Entry into a Material Definitive Agreement (Standby Equity Purchase Agreement and Convertible Notes) with YA II PN, LTD ("Yorkville").
Key Financial Metrics and Capital Structure
This filing details a financing arrangement rather than operational financial results. Key terms include:
- SEPA Commitment: Yorkville agreed to purchase up to $20.0 million of common stock at the Company's discretion.
- Pre-Paid Advance (Debt): Yorkville advanced up to $6.0 million in two tranches in exchange for convertible promissory notes.
- Tranche 1: $3.72 million disbursed October 27, 2025 (Principal: $4.0 million).
- Tranche 2: $1.86 million pending registration effectiveness and stockholder approval (Principal: $2.0 million).
- Debt Terms:
- Interest Rate: 8% annually (increases to 18% upon default).
- Maturity: October 24, 2026.
- Repayment: Monthly installments beginning 75 days after the agreement date, repayable in cash or via stock issuance under the SEPA.
- Conversion Price: Initial fixed price of $1.50 per share (subject to anti-dilution adjustments).
- Issuance Limits:
- Exchange Cap: 7,180,504 shares (19.99% of outstanding stock) unless stockholder approval is obtained at the December 19, 2025 annual meeting.
- Beneficial Ownership Cap: Yorkville cannot exceed 4.99% beneficial ownership without notice.
- Transaction Costs:
- Structuring Fee: $25,000 cash + 131,909 shares of common stock (Commitment Shares).
- Finder's Fee: 8.0% of Pre-Paid Advance proceeds plus $18,000/month for 12 months (payable upon raising $5.0M+ in additional financing).
Material Changes and Liquidity Impact
The filing does not report changes in revenue or operating margins. The primary material change is the immediate increase in liquidity and the creation of a direct financial obligation:
- Liquidity: The Company received $3.72 million in cash on October 27, 2025, with an additional $1.86 million available upon satisfaction of conditions.
- Debt Obligation: The Company now carries $6.0 million in principal debt obligations (via Convertible Notes) with mandatory monthly repayment schedules starting in early 2026.
- Dilution Risk: Potential issuance of up to 7,180,504 shares immediately, with the possibility of higher issuance if stockholder approval is granted in December 2025.
Outlook, Management Commentary, and Risks
Use of Proceeds:
- Support Phase 2 trial of lead asset JOTROL for Parkinson's Disease.
- Accelerate direct-to-consumer marketing and sales of the Nugevia.com nutritional product line.
- Working capital and general corporate purposes.
Management Commentary: The Company controls the timing and amount of stock sales under the SEPA, allowing flexibility based on market conditions. Proceeds from future SEPA advances will primarily be used to repay the Convertible Notes until fully satisfied.
Risks and Contingencies:
- Stockholder Approval: The second tranche of funding and the ability to issue shares beyond the 19.99% cap depend on approval at the December 19, 2025 annual meeting.
- Repayment Obligation: Failure to make monthly installment payments could trigger an Event of Default, increasing interest to 18% and allowing conversion at a discounted "Variable Price."
- Restrictions: The Company is prohibited from entering into other "Variable Rate Transactions" or equity lines of credit until the Convertible Notes are repaid. Executive bonuses and related party debt repayments are also restricted.
Investor Verification Checklist
- Verify the outcome of the December 19, 2025 Annual Stockholders' Meeting regarding the removal of the 19.99% Exchange Cap.
- Monitor the daily VWAP of JUNS stock to assess the potential dilution impact of the $1.50 conversion price and the 97% of lowest VWAP pricing for SEPA advances.
- Confirm the effective date of the Registration Statement required for the second tranche of the Pre-Paid Advance.
- Review future 10-Q filings for the monthly repayment schedule of the Convertible Notes and any cash burn rate relative to the new liquidity.
- Check for any short sale or hedging activity by Yorkville, which is prohibited under the agreement.